ROCKVILLE, Md. & EDMONTON, Alberta / Nov 14, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
| Last Trade: | US$12.16 |
| Daily Change: | 0.06 0.50 |
| Daily Volume: | 851,764 |
| Market Cap: | US$1.600B |
July 31, 2025 June 30, 2025 June 29, 2025 May 12, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
